Drug samples falling out of favor as pharma sales tool

Drug samples falling out of favor as pharma sales tool
Drug samples falling out of favor as pharma sales tool

Drug samples were once  standard in pharmaceutical sales calls. But a report says that isn't so true now. Cegedim Strategic Data found a 25% dip in industry support for samples bewteen 2007 and 2011—from just under $8.5 billion to about $6 billion.

The drop is part of a shift in the relationship between pharma's traditional methods of promotion—sampling and detailing—and a landscape in which physician behavior is dictated by type of practice, said consultant Richard Vanderveer.

According to  Vanderveer, doctors used to be more inclined to meet with a sales representative, discuss a drug's merits and get samples—but current clinicians, pressed for time, are cutting sales meetings short. He also notes that treatment protocols at larger care organizations may be making samples less relevant.

CSD says sales reps are now 36% less likely to walk into a physician's office with the intent of leaving a sample—unless they are calling on a new doctor with no prescribing history. In those cases, CSD found samples increase the likelihood of a prescription by 81%, compared with a 51% uptake rate among new doctors who didn't get samples.

Vanderveer says the data also show a shift in sales calls themselves. He thinks trained medical liaisons will have a larger role than traditional sales representatives, as doctors will be more likely to welcome them—whether or not the visit includes samples.
You must be a registered member of MMM to post a comment.

Next Article in Features

Content marketing is not advertising in the old sense. In its use of social media, content marketing challenges consumers while relying on their input. It is proactive and responsive to their concerns, needs and energy. Content marketing has become the new voice of marketing. Learn what you need to know and how pharma marketers can adapt to this innovative venture into social media by clicking here for access.

Email Newsletters